The U.S. Food and Drug Administration (FDA) is testing a new way to inspect drug manufacturing facilities to make sure they follow safety rules. These inspections are shorter—just one day long—instead of the usual longer visits. The goal is to check more facilities without losing the high standards of safety checks. This new approach will not replace the longer inspections but will work alongside them to help the FDA focus its resources where they are most needed. It will also help the FDA create better risk models to predict which facilities might have problems in the future. The shorter inspections will look at things like repeated compliance issues, risks specific to certain facilities, and differences between what a facility says it does and what it actually does. This information will help the FDA target its future oversight more effectively. The FDA launched this pilot program in April, and it will continue through 2026. So far, the FDA has completed about 46 one-day inspections, with most results showing no problems that required action. The agency is still studying the data from these inspections to see how this new approach can improve its overall inspection strategy. FDA Commissioner Marty Makary explained, “One-day inspections can make our safety checks stronger by letting us focus our time and resources where they are most needed. For the FDA, this means we can check more facilities and still keep high safety standards. For drug companies, these shorter inspections can give them quick feedback while keeping disruptions to their work as small as possible.” Elizabeth Miller, the FDA’s Associate Commissioner for Inspections and Investigations, added, “We are carefully reviewing all the data from these inspections, including trends in results, risk signals, and feedback from inspectors, to see how this approach can make our overall inspection strategy better.” Earlier this year, the FDA also started another program called PreCheck to encourage drug companies to build new manufacturing facilities. Additionally, the FDA is working on real-time clinical trials to help develop new treatments faster. These efforts are all part of the FDA’s plan to improve how it regulates drugs while keeping safety a top priority.